MK-677 Dosage Guide: Optimal Dose, Timing & Cycle Length

Overview

MK-677 (ibutamoren mesylate) is an orally active growth hormone secretagogue that stimulates GH release by mimicking the action of ghrelin at the GHS-R1a receptor. Unlike injectable peptides such as GHRP-6 or hexarelin, MK-677 is taken by mouth once daily, making it one of the most accessible growth hormone-related compounds. Clinical trials have used doses of 5 mg, 10 mg, 25 mg, and 50 mg daily, with 25 mg emerging as the standard effective dose that maximizes GH and IGF-1 elevation while maintaining an acceptable side effect profile. This guide covers the clinical evidence behind dosing, timing strategies, cycle length considerations, and practical protocols based on published research.

Clinical Dosing: What the Trials Used

The dosing evidence for MK-677 comes primarily from a series of clinical trials conducted by Merck Research Laboratories in the late 1990s and early 2000s. These trials provide the foundation for every dosing recommendation in clinical and self-experimentation contexts. The pivotal dose-response study by Copinschi et al. (1997) tested 5 mg and 25 mg daily in healthy young men, finding that 25 mg produced significantly greater increases in GH pulse amplitude (approximately 1.8-fold increase in mean 24-hour GH concentration) and IGF-1 levels (approximately 40-60% increase from baseline) compared to 5 mg. The 25 mg dose also restored the youthful frequency and amplitude of GH pulsatile secretion in elderly subjects within two weeks of treatment. A longer-term study by Murphy et al. (1998) administered 25 mg daily to healthy older adults for 12 months, demonstrating sustained IGF-1 elevation of approximately 40% above baseline throughout the study period without evidence of GH receptor desensitization. This is particularly notable because injectable GH secretagogues often show diminished response over time. The 2-year extension of this study confirmed that IGF-1 remained elevated at 12 and 24 months, though the effect on body composition (lean mass gain, fat mass) was modest in this elderly population. A separate trial using 50 mg daily found no additional benefit over 25 mg but did increase side effects, particularly appetite stimulation and edema, establishing 25 mg as the clinical ceiling dose.

• 5 mg daily: Modest GH increase; insufficient for most therapeutic goals
• 10 mg daily: Moderate GH/IGF-1 elevation; used as a starting dose to assess tolerance
• 25 mg daily: Standard clinical dose; maximizes GH/IGF-1 response in most individuals
• 50 mg daily: No additional efficacy over 25 mg; increased side effects

Optimal Timing: Why Pre-Bed Dosing Is Preferred

The timing of MK-677 administration has meaningful practical implications, even though the compound has a long half-life of approximately 24 hours that maintains relatively stable plasma levels regardless of when it is taken. Pre-bed dosing (30-60 minutes before sleep) has become the consensus recommendation for two evidence-based reasons. First, MK-677 produces its strongest GH pulse within 1-2 hours of ingestion. When taken before bed, this acute pulse is superimposed onto the natural nocturnal GH surge that occurs during slow-wave sleep, potentially amplifying the total GH exposure during the period when the body is most physiologically primed for growth and repair processes. Sleep-associated GH release accounts for approximately 70% of daily GH output, and augmenting this window makes pharmacological sense. Second, the most common and immediate side effect of MK-677 is appetite stimulation, which typically peaks 1-3 hours after dosing due to the compound's direct agonism of the ghrelin receptor (GHS-R1a). By dosing before bed, users sleep through the peak hunger period, avoiding unnecessary caloric intake that could undermine body composition goals. Some users report that morning dosing leads to significant overeating during the day. For individuals who find that MK-677 disrupts sleep quality — a minority report vivid dreams or restlessness — morning dosing is a reasonable alternative. The 24-hour half-life ensures that GH and IGF-1 remain elevated regardless. Taking MK-677 with or without food does not significantly affect absorption, though some users report reduced gastric discomfort when taken with a small snack.

GH and IGF-1 Response by Dose

Understanding the dose-response relationship between MK-677 and its primary biomarkers helps users set realistic expectations and evaluate whether their protocol is working. At 25 mg daily, clinical data shows the following typical responses. IGF-1 increases approximately 40-60% above baseline within 2-4 weeks and remains elevated for the duration of use. In the Murphy et al. study, mean IGF-1 rose from approximately 190 ng/mL to approximately 280 ng/mL in elderly subjects — a clinically significant increase that brings levels into the upper-normal range for younger adults. Growth hormone mean 24-hour concentrations increase approximately 1.5-1.8 fold, with the peak pulse amplitude (not mean level) increasing more dramatically. GH remains pulsatile rather than continuously elevated, which is important because pulsatile release is associated with more favorable metabolic outcomes than continuous GH exposure. At 10 mg daily, IGF-1 elevation is more modest — approximately 20-35% above baseline — which may be sufficient for individuals seeking anti-aging or recovery benefits without maximizing GH output. The dose-response curve between 10 mg and 25 mg appears to be roughly linear, while the curve between 25 mg and 50 mg is flat (no additional benefit). IGFBP-3, the primary binding protein for IGF-1, also increases in parallel with IGF-1, maintaining the IGF-1/IGFBP-3 ratio within normal physiological limits. This is in contrast to exogenous GH injection, which can produce supraphysiological free IGF-1 levels. Cortisol shows a transient increase in some studies but does not sustain at clinically concerning levels during chronic use at 25 mg. Prolactin is not meaningfully affected at standard doses.

• IGF-1: +40-60% at 25 mg; +20-35% at 10 mg; plateaus above 25 mg
• GH mean 24h levels: +50-80% at 25 mg; pulsatile pattern preserved
• IGFBP-3: Increases proportionally with IGF-1; free IGF-1 ratio remains normal
• Cortisol: Transient mild increase; not clinically significant at standard doses
• Prolactin: No meaningful change at 10-25 mg

Cycle Length: 8-12 Weeks vs Continuous Use

The question of cycle length is one of the most debated topics in MK-677 use, and the clinical data provides unusually clear guidance compared to most peptides. The Murphy et al. studies demonstrated that MK-677 at 25 mg daily maintained its GH and IGF-1 elevating effects for up to 2 years without tolerance development. This is a critically important finding because it means MK-677 does not exhibit the receptor desensitization that limits the long-term efficacy of many GH secretagogues. However, continuous long-term use also carries cumulative risk considerations that temper enthusiasm for indefinite protocols. Blood glucose and insulin sensitivity represent the primary concern with extended MK-677 use. The 2-year study by Nass et al. (2008) found that while GH and IGF-1 remained elevated, fasting glucose increased by approximately 5-10 mg/dL and insulin resistance (measured by HOMA-IR) worsened modestly. In individuals with pre-existing metabolic risk factors, this could push glucose tolerance from normal into impaired ranges. The community has generally adopted 8-12 week cycles as a pragmatic compromise: long enough to achieve meaningful IGF-1 elevation and body composition benefits, short enough to limit metabolic side effects. A common pattern is 8-12 weeks on, followed by 4-8 weeks off. Some users run 16-week cycles or longer, particularly when stacking with other compounds, but metabolic monitoring (fasting glucose, HbA1c) becomes more important with extended use. For anti-aging purposes, some clinicians prescribe lower doses (10-15 mg) continuously on the basis that the metabolic impact is dose-dependent and lower doses may not meaningfully impair glucose metabolism.

• Short cycle (8 weeks): Conservative approach; suitable for first-time users
• Standard cycle (12 weeks): Most common in the self-experimentation community; balances efficacy and risk
• Extended cycle (16-24 weeks): Used by experienced users; requires metabolic monitoring
• Continuous low-dose (10 mg indefinite): Anti-aging protocol; less evidence for safety

Starting Protocol: How to Begin MK-677

A sensible starting protocol accounts for individual variation in MK-677 tolerance — particularly regarding appetite stimulation, water retention, and blood glucose effects — while building toward the effective clinical dose. The following stepped approach is commonly used in both clinical practice and the self-experimentation community. Begin with 10 mg daily for the first 1-2 weeks, taken 30-60 minutes before bed with a small amount of water. This allows assessment of individual tolerance to appetite stimulation, any sleep effects, and baseline water retention. Most users notice increased appetite within 2-3 days and mild water retention (1-3 lbs) within the first week. If 10 mg is well-tolerated after 1-2 weeks, increase to 15 mg daily for another 1-2 weeks. This intermediate step is optional but useful for individuals who experienced significant appetite increase or water retention at 10 mg. If no concerning effects are present at 15 mg, increase to 25 mg daily for the remainder of the cycle. The total cycle length should be 8-12 weeks from the start of dosing, including the titration period. Blood work is recommended at baseline (before starting) and at 4-6 weeks into the cycle. Key markers to test include IGF-1, fasting glucose, fasting insulin, and a comprehensive metabolic panel. If fasting glucose rises above 100 mg/dL or increases more than 10 mg/dL from baseline, consider reducing the dose to 10-15 mg or discontinuing. Post-cycle, IGF-1 levels typically return to baseline within 2-4 weeks after cessation. No formal post-cycle therapy (PCT) is required because MK-677 does not suppress the hypothalamic-pituitary-gonadal axis. Testosterone, LH, and FSH are not affected.

• Weeks 1-2: 10 mg daily before bed; assess tolerance
• Weeks 3-4: 15 mg daily (optional intermediate step)
• Weeks 5-12: 25 mg daily; full clinical dose
• Blood work: Baseline + 4-6 weeks (IGF-1, fasting glucose, insulin, CMP)
• Post-cycle: No PCT required; IGF-1 normalizes within 2-4 weeks

Stacking Considerations

MK-677 is frequently used in combination with other compounds, and understanding the pharmacological interactions helps guide safe stacking decisions. The most common stack is MK-677 with a GHRH analog (such as CJC-1295 with DAC or modified GRF 1-29). This combination leverages complementary mechanisms: MK-677 acts at the ghrelin receptor to amplify GH pulse amplitude, while GHRH analogs act at the GHRH receptor to increase pulse frequency. The result is a synergistic increase in total GH output that exceeds what either compound achieves alone. However, this also amplifies side effects — particularly appetite, water retention, and blood glucose impact — so starting doses should be conservative when stacking. MK-677 is also commonly combined with SARMs (selective androgen receptor modulators) by the self-experimentation community, though this combination has no clinical trial support. The rationale is that elevated IGF-1 from MK-677 may enhance the anabolic effects of SARMs, though this is theoretical. From a safety perspective, the key consideration when stacking MK-677 with any compound is additive metabolic burden. MK-677 already impairs insulin sensitivity modestly; combining it with compounds that also affect glucose metabolism (such as certain SARMs or exogenous GH) increases the cumulative risk of metabolic dysfunction. Users who stack should monitor fasting glucose and HbA1c more frequently. MK-677 does not need to be cycled with injectable peptides — it can be run alongside GHRP/GHRH protocols or used as a standalone during off-periods from injectable secretagogues. Its oral bioavailability and once-daily dosing make it a practical baseline GH support tool.

Managing Common Side Effects Through Dosing Adjustments

The dose-dependent nature of MK-677 side effects means that many can be managed through dosing adjustments rather than discontinuation. Appetite stimulation is the most common side effect and is a direct pharmacological consequence of ghrelin receptor activation. At 25 mg, most users report significantly increased appetite within 1-3 hours of dosing. The primary management strategy is pre-bed dosing (sleeping through peak hunger). If appetite remains problematic, reducing to 10-15 mg substantially attenuates this effect while maintaining meaningful IGF-1 elevation. Water retention (peripheral edema) occurs in approximately 10-20% of users at 25 mg and is most noticeable in the hands, ankles, and face during the first 2-4 weeks. This effect is dose-dependent and typically stabilizes or reduces after the initial adaptation period. Reducing sodium intake, increasing water consumption, and lowering the dose to 10-15 mg are effective management strategies. In clinical trials, edema resolved in all subjects after discontinuation and was not associated with cardiac or renal dysfunction. Blood glucose elevation is the most clinically significant side effect and the primary reason for cycle length limits. At 25 mg, fasting glucose typically increases 5-10 mg/dL, which is manageable for metabolically healthy individuals but concerning for those with pre-diabetes or insulin resistance. Dose reduction to 10 mg substantially reduces the glucose impact. Some users add berberine (500 mg twice daily) or metformin (if prescribed) to counteract glucose effects, though this should be discussed with a physician. Lethargy and fatigue are reported by some users during the first 1-2 weeks, potentially related to increased GH-mediated fluid shifts and the sedative-adjacent effects of ghrelin receptor activation. This typically resolves with continued use.

• Appetite: Dose before bed; reduce to 10-15 mg if persistent
• Water retention: Reduce sodium; ensure adequate hydration; typically resolves by week 4
• Blood glucose: Monitor fasting glucose; reduce dose or discontinue if >100 mg/dL
• Lethargy: Usually transient (1-2 weeks); timing dose before bed helps
• Numbness/tingling: Suggests carpal tunnel compression from fluid retention; reduce dose

References

1. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism (1998) — PubMed
2. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial (2008) — PubMed
3. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects (1997) — PubMed
4. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure (1997) — PubMed